These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 27071522)

  • 21. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
    Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
    J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China.
    Zhang Y; Zhang W; Li J; Duan M; Han B; Zhu T; Zhuang J; Cai H; Cao X; Chen M; Zhou D
    Ann Hematol; 2019 Jan; 98(1):143-150. PubMed ID: 30209556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas.
    Liu X; Yang M; Wu M; Zheng W; Xie Y; Zhu J; Song Y; Liu W
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):443-449. PubMed ID: 30511217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.
    Foss F; Pro B; Miles Prince H; Sokol L; Caballero D; Horwitz S; Coiffier B
    Cancer Med; 2017 Jan; 6(1):36-44. PubMed ID: 27981793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial).
    Park BB; Kim WS; Suh C; Hong JY; Yang DH; Lee WS; Do YR; Koh YI; Won JH; Kim MK; Jo JC; Hyun SY; Kim JA; Oh YH; Lee SS
    Leuk Lymphoma; 2019 Dec; 60(13):3251-3257. PubMed ID: 31170847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.
    Mahadevan D; Unger JM; Spier CM; Persky DO; Young F; LeBlanc M; Fisher RI; Miller TP
    Cancer; 2013 Jan; 119(2):371-9. PubMed ID: 22833464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.
    Ruan J; Zain J; Palmer B; Jovanovic B; Mi X; Swaroop A; Winter JN; Gordon LI; Karmali R; Moreira J; Petrich AM; Pro B
    Blood Adv; 2023 Oct; 7(19):5771-5779. PubMed ID: 37327113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts.
    Mehta-Shah N; Lunning MA; Moskowitz AJ; Boruchov AM; Ruan J; Lynch P; Hamlin PA; Leonard J; Matasar MJ; Myskowski PL; Marzouk E; Nair S; Sholklapper T; Minnal V; Palomba ML; Vredenburgh J; Kumar A; Noy A; Straus DJ; Zelenetz AD; Schoder H; Rademaker J; Schaffer W; Galasso N; Ganesan N; Horwitz SM
    Am J Hematol; 2021 Oct; 96(10):1211-1222. PubMed ID: 34251048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma.
    Yao YY; Tang Y; Zhu Q; Zhuang Y; Cheng YM; Wang L; Zou LF
    Leuk Lymphoma; 2013 Jun; 54(6):1194-200. PubMed ID: 23061678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial.
    Damaj G; Gressin R; Bouabdallah K; Cartron G; Choufi B; Gyan E; Banos A; Jaccard A; Park S; Tournilhac O; Schiano-de Collela JM; Voillat L; Joly B; Le Gouill S; Saad A; Cony-Makhoul P; Vilque JP; Sanhes L; Schmidt-Tanguy A; Bubenheim M; Houot R; Diouf M; Marolleau JP; Béné MC; Martin A; Lamy T
    J Clin Oncol; 2013 Jan; 31(1):104-10. PubMed ID: 23109692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
    Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
    Horwitz S; Coiffier B; Foss F; Prince HM; Sokol L; Greenwood M; Caballero D; Morschhauser F; Pinter-Brown L; Iyer SP; Shustov A; Nichols J; Balser J; Balser B; Pro B
    Ann Oncol; 2015 Apr; 26(4):774-779. PubMed ID: 25605745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
    Zinzani PL; Magagnoli M; Bendandi M; Orcioni GF; Gherlinzoni F; Albertini P; Pileri SA; Tura S
    Ann Oncol; 1998 Dec; 9(12):1351-3. PubMed ID: 9932168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
    Dong M; He XH; Liu P; Qin Y; Yang JL; Zhou SY; Yang S; Zhang CG; Gui L; Zhou LQ; Shi YK
    Med Oncol; 2013 Mar; 30(1):351. PubMed ID: 23269584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
    Santoro A; Mazza R; Pulsoni A; Re A; Bonfichi M; Zilioli VR; Salvi F; Merli F; Anastasia A; Luminari S; Annechini G; Gotti M; Peli A; Liberati AM; Di Renzo N; Castagna L; Giordano L; Carlo-Stella C
    J Clin Oncol; 2016 Sep; 34(27):3293-9. PubMed ID: 27382096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
    Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
    Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.
    Li L; Duan W; Zhang L; Li X; Fu X; Wang X; Wu J; Sun Z; Zhang X; Chang Y; Nan F; Yan J; Li Z; Young KH; Zhang M
    Br J Haematol; 2017 Sep; 178(5):772-780. PubMed ID: 28597542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial.
    Yhim HY; Kim T; Kim SJ; Shin HJ; Koh Y; Kim JS; Park J; Park GS; Kim WS; Moon JH; Yang DH
    Ann Oncol; 2021 Apr; 32(4):552-559. PubMed ID: 33352201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Erland JB; Baker M; Scullin DC; Shaffer DW; Greco FA;
    Cancer Invest; 2003 Apr; 21(2):193-9. PubMed ID: 12743984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.